CHRISTOPHER M. STARR - 14 Jul 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Director
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
14 Jul 2025
Transactions value $
-$671,936
Form type
4
Filing time
16 Jul 2025, 21:03:50 UTC
Previous filing
07 Mar 2025
Next filing
08 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
STARR CHRISTOPHER M Director 1000 SKOKIE BLVD SUITE 350, WILMETTE /s/ Quan Vu, Attorney-in-fact 16 Jul 2025 0001235470

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Exercise of in-the-money or at-the-money derivative security $84.00 +16.8K +324.76% $0.01 22K 14 Jul 2025 Direct F1
transaction MNPR Common Stock Sale -$672K -16.8K -76.46% $40.00 5.17K 14 Jul 2025 Direct F2
holding MNPR Common Stock 9.88K 14 Jul 2025 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Exercise of in-the-money or at-the-money derivative security $0 -16.8K -100% $0.00 0 14 Jul 2025 Common Stock 16.8K $0.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction involved a cash exercise of stock options.
F2 The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 9,880 shares of common stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee
F4 Reflects options to purchase up to 16,800 shares of common stock granted to Dr. Starr on April 4, 2016, for his services as a director of Monopar Therapeutics. The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.